中国药业2026，Vol.35Issue(4)：1-9,9.DOI:10.3969/j.issn.1006-4931.2026.04.001
京津冀生物医药临床研究实力分析
Analysis of Clinical Research Capacity in Biomedicine in the Beijing-Tianjin-Hebei Region
摘要
Abstract
Objective To analyze the clinical research capacity in the biomedical field in the Beijing-Tianjin-Hebei region.Methods The clinical research data of the biomedical field in the Beijing-Tianjin-Hebei region from 2015 to 2024 were collected through ClinicalTrials.gov database.Bibliometric methods were used to analyze the registation scale,research design,implementation characteristics,and cooperation of clinical research in the this fieled among the three regions.Results In terms of the registation scale of clinical research,a total of 8 722 clinical studies in the biomedical field were registered in the Beijing-Tianjin-Hebei region,of which the number in Beijing(7 530 studies)was much higher than that in Tianjin(2 363 studies)and Hebei(1 027 studies),all showing a growth trend.In terms of research design and implementation characteristics,the type of research was mainly intervention research(90.98%);the proportion of phase Ⅲ drug clinical trials was relatively high(23.86%);the intervention type was mainly drugs(83.73%),but the proportion of instruments and other types of research in Beijing(16.03%,2.34%)was higher than those in Tianjin(8.08%,1.95%)and Hebei(11.30%,0.78%).Most studies did not set gender restrictions(91.01%),and the majority of participants were adults or elderly populations(79.67%);the proportion of research at the recruitment stage was 30.22%,and the proportion of research results published was 8.35%.In terms of cooperation of clinical research,the proportion of single-institution clinical research,domestic cooperative clinical research and international cooperative clinical research were 55.26%,27.81%and 16.92%,respectively,and the participation in different types of cooperative clinical research in Beijing were highest.In domestic cooperative clinical research,the Beijing-Tianjin-Hebei region maintained a high level of cooperation with Guangdong,Jiangsu and other provinces;in international cooperation,the United States,Spain and South Korea were the main partners,though there were certain differences in the cooperation patterns among the three regions.Conclusions The number of clinical research in the biomedical field of the Beijing-Tianjin-Hebei region continues to grow,with the characteristics of resource agglomeration and collaborative development.In the future,we should promote the cross-regional sharing of high-quality clinical resources in Beijing-Tianjin,establish differentiated functional positioning,and deepen the dual framework of domestic collaboration and international cooperation.关键词
京津冀/生物医药/临床研究/区域协同/文献计量学Key words
Beijing-Tianjin-Hebei region/biomedicine/clinical research/regional collaboration/bibliometric分类
医药卫生引用本文复制引用
卢岩,张婷,陈佩璇,王瑛昊,杨君,欧阳昭连..京津冀生物医药临床研究实力分析[J].中国药业,2026,35(4):1-9,9.基金项目
北京市社会科学基金项目(重点项目)[24JCB024]. （重点项目）
